Table 8.
Outcomes predicted by models for one birth cohort in Sear-region
| POLYMODa | Roxanne | CoRoVa | |
|---|---|---|---|
| Undiscounted cases | |||
| Mild | 216,205 | 276,861 | 299,907 |
| Moderate | 114,255 | 159,129 | 127,020 |
| Severe | 11,887 | 22,086 | 12,325 |
| Nosocomial | 3,923 | 4,748 | 6,309 |
| Deaths | 1,486 | 2,752 | 2,366 |
| Outpatient | 126,142 | 159,129 | 127,020 |
| Inpatient (comm. acq.) | 11,887 | 22,086 | 12,325 |
| Discounted savings | |||
| Outpatient | $1,135,274 | $1,391,130 | $1,852,744 |
| Inpatient | $2,208,959 | $2,975,397 | $1,712,409 |
| Indirect | $1,267,227 | $1,213,598 | $948,564 |
| Discounted net costsb (*1000) | $15,424 | $ 19,969-39,083 | $ 20,545-39,423 |
| Discounted QALYs | |||
| Mortality | 41,822 | 75,969 | 65,244 |
| Morbidity | 1,261 | 1,731 | 1,462 |
a. Approximations for one cohort from the multi-cohort results; b. Health-care perspective and range given for previous upper and lower vaccine prices if appropriate.